Researcher at Peking University People's Hospital Publishes Research in Acute Promyelocytic Leukemia (Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia).

A recent study conducted at Peking University People's Hospital explored the role of cytoreductive chemotherapy in the prognosis of patients with low-risk acute promyelocytic leukemia (APL). The study analyzed consecutive low-risk APL patients who received all-trans retinoic acid (ATRA) plus arsenic for induction and consolidation therapy. The results showed that cytoreductive chemotherapy had a dual effect of cytoreduction and prevention of relapse in low-risk APL. The study suggested that oral etoposide combined with ATRA and arsenic could be a regimen with low relapse, good tolerance, and convenience. A prospective, randomized, controlled study comparing oral etoposide with intravenous daunorubicin is currently underway. [Extracted from the article]